Advertisement

DNP - Der Neurologe & Psychiater

, Volume 18, Issue 5, pp 22–26 | Cite as

Seltene, aber gefährliche Partydroge

Gammahydroxybutyrat und seine psychiatrischen Implikationen

Fortbildung
  • 44 Downloads

Gammahydroxybutyrat (GHB) ist in der Drogen- und Partyszene weit verbreitet. Psychiatrische Kliniken und Rettungsstellen werden daher zunehmend mit Problemen rund um die Substanz konfrontiert. Dieser Artikel informiert über die Wirkungen von GHB sowie die Behandlungsoptionen bei Intoxikation und Entzug.

Literatur

  1. 1.
    Nemeth Z, Kun B, Demetrovics Z. The involvement of gamma-hydroxybutyrate in reported sexual assaults: a systematic review. J Psychopharmacol 2010;24(9): 1281–7.CrossRefPubMedGoogle Scholar
  2. 2.
    Europäische Beobachtungsstelle für Drogen und Drogensucht (EMCDDA). Europäischer Drogenbericht 2016. Verfügbar: http://www.emcdda.europa.eu/publications/edr/trends-developments/2016 (letzter Zugriff: 31.01.2017).
  3. 3.
    Dines AM, Wood DM, Yates C et al. Acute recreational drug and new psychoactive substance toxicity in Europe: 12 months data collection from the European Drug Emergencies Network (Euro-DEN). Clin Toxicol 2015, 53(9): 893–900.CrossRefGoogle Scholar
  4. 4.
    Nelson T, Kaufman E, Kline J et al. The extraneural distribution of gamma-hydroxybutyrate. J Neurochem 1981; 37(5): 1345–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Corkery JM, Loi B, Claridge H et al. Gamma hydroxybutyrate (GHB), gamma butyrolactone (GBL) and 1,4-butanediol (1,4-BD; BDO): A literature review with a focus on UK fatalities related to non-medical use. Neuroscience Biobehavioral Rev 2015;53: 52–78.CrossRefGoogle Scholar
  6. 6.
    Carai MA, Colobo G, Reali R et al. Central effects of 1,4-butanediol are mediated by GABA(B) receptors via its conversion into gamma-hydroxybutyric acid. Eur J Pharmacol 2002;441(3):157–63.CrossRefPubMedGoogle Scholar
  7. 7.
    Galloway GP, Frederick SL, Staggers Jr, FE et al. Gamma-hydroxybutyrate: An emerging drug of abuse that causes physical dependence. Addiction 1997;92(1):89–96.CrossRefPubMedGoogle Scholar
  8. 8.
    Palatini P, Tedeschi L, Frison G et al. Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers. Eur J Clin Pharmacol 1993;45(4):353–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Brenneisen R, Elsohly MA, Murphy TP et al. Pharmacokinetics and excretion of gamma-hydroxybutyrate (GHB) in healthy subjects. J Anal Toxicol 2004;28: 625–30.CrossRefPubMedGoogle Scholar
  10. 10.
    Roth RH, Delgado JMR, Giarman NJ. γ-Butyrolactone and ?-hydroxybutyric acid - II. The pharmacologically active form. Int J Neuropharmacol 1966: 5(6): 421–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Hoes MJ, Vree TB, Guelen PJ. Gamma-hydroxybutyric acid as hypnotic. Clinical and pharmacokinetic evaluation of gamma-hydroxybutyric acid as hypnotic in man. Encephale 1980;6(1):93–9.PubMedGoogle Scholar
  12. 12.
    Lettieri J, Fung HL. Improved pharmacological activity via pro-drug modification: Comparative pharmacokinetics of sodium gamma-hydroxybutyrate and gamma-butyrolactone. Res Commun Chem Pathol Pharmacol 1978;22(1):107–18.PubMedGoogle Scholar
  13. 13.
    Arena C, Fung HL. Absorption of sodium gamma-hydroxybutyrate and its prodrug gamma-butyrolactone: Relationship between in vitro transport and in vivo absorption. J Pharm Sci 1980;69(3):356–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Thai D, Dyer JE, Jacob P et al. Clinical pharmacology of 1,4-butanediol and gamma-hydroxybutyrate after oral 1,4-butanediol administration to healthy volunteers. Clin Pharm Ther 2007;81(2): 178–84.CrossRefGoogle Scholar
  15. 15.
    Galldiks N, Kadow I, Bechdolf A et al. Symptomvielfalt nach Konsum der Droge Gamma-Hydroxybuttersäure (GHB). Fortschr Neurol Psychiatr 2011;79: 21–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Madea B, Musshoff F. K.-o.-Mittel: Häufigkeit, Wirkungsweise, Beweismittelsicherung. Dtsch Arztebl 2009;106: 341–7.Google Scholar
  17. 17.
    Freudenmann RW, Baumgarten E, Hawlik AE et al. Liquid ecstasy in general psychiatry: A case series. Fortschr Neurol Psychiat 2013; 81: 88–94.CrossRefPubMedGoogle Scholar
  18. 18.
    Bourne A, Reid D, Hickson F et al. The Chemsex Study: Drug Use in Sexual Settings Among Gay and Bisex-ual Men in Lambeth, Southwark & Lewisham. Sigma Research, LondonSchool of Hygiene & Tropical Medicine, London 2014. Available at: http://www.sigmaresearch.org.uk/projects/project59/ (letzter Zugriff 31.01.2017).
  19. 19.
    Andresen H, Sprys N, Schmoldt A et al. Gamma-hydroxybutyrate in urine and serum: Additional data supporting current cut-off recommendations. Forensic Sci Int 2010; 200(1-3): 93–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Schütz H, Jansen M, Verhoff M. Vom Alkohol zum Liquid Ecstasy (GHB) - ein Überblick über alte und moderne K.-o.-Mittel - Teil 3: Gamma-Hydroxybuttersäure (GHB, “Liquid Ecstasy”). Arch Kriminol 2011; 228: 151–9.PubMedGoogle Scholar
  21. 21.
    Snead OC 3rd, Gibson KM. Gamma-hydroxybutyric acid. N Engl J Med 2005; 352: 2721–32.CrossRefPubMedGoogle Scholar
  22. 22.
    van Amsterdam JGC, van Laar M, Brunt JM et al. Risk assessment of gamma-hydroxybutyric acid (GHB) in the Netherlands. Regul Toxicol Pharmacol 2012; 63(1): 55–63.CrossRefPubMedGoogle Scholar
  23. 23.
    Schep LJ, Knudsen K, Slaughter RJ et al. The clinical toxicology of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol. Clin Toxicol 2012: 50: 458–70.CrossRefGoogle Scholar
  24. 24.
    Tancredi DN, Shannon MW. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 30 - 2003. A 21-year-old man with sudden alteration of mental status. N Engl J Med 2003; 349: 1267–75.CrossRefPubMedGoogle Scholar
  25. 25.
    Chin RL, Sporer KA, Cullison B et al. Clinical course of gamma-hydroxybutyrate overdose. Ann Emerg Med 1998;31:716–22.CrossRefGoogle Scholar
  26. 26.
    Liechti ME, Kunz I, Greminger P et al. Clinical features of gamma-hydroxybutyrate and gamma-butyrolactone toxicity and concomitant drug and alcohol use. Drug Alcohol Depend 2006; 81: 323–6.CrossRefPubMedGoogle Scholar
  27. 27.
    Suner S, Szlatenyi CS, Wang RY. Pediatric gamma hydroxybutyrate intoxication. Acad Emerg Med 1997; 4: 1041–5.CrossRefPubMedGoogle Scholar
  28. 28.
    Zvosec DL, Smith SW, McCutcheon JR et al. Adverse events, including death, associated with the use of 1,4-butanediol. N Engl J Med 2001; 344: 87–94.CrossRefPubMedGoogle Scholar
  29. 29.
    Thomas G, Bonner S, Gascoigne A. Coma induced by abuse of gamma-hydroxybutyrate (GBH or liquid ecstasy): A case report. Br Med J 1997; 314: 35–6.CrossRefGoogle Scholar
  30. 30.
    Caldicott DG, Kuhn M. Gamma-hydroxybutyrate overdose and physostigmine: Teaching new tricks to an old drug? Ann Emerg Med 2001; 37: 99–102.CrossRefPubMedGoogle Scholar
  31. 31.
    Yates SW, Viera AJ. Physostigmine in the treatment of gammahydroxybutyric acid overdose. Mayo Clin Proc 2000; 75: 401–2.CrossRefPubMedGoogle Scholar
  32. 32.
    Bania TC, Chu J: Physostigmine does not effect arousal but produces toxicity in an animal model of severe gamma-hydroxybutyrate intoxication. Acad Emerg Med 2005; 12: 185–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Van Noorden MS, van Dongen L, Zitman FG et al. Gamma-hydroxybutyrate withdrawal syndrome: Dangerous but not well-known. Gen Hosp Psychiatry 2009; 31: 394–6.CrossRefPubMedGoogle Scholar
  34. 34.
    Rosenberg MH, Deerfield LJ, Baruch EM. Two cases of severe gamma-hydroxybutyrate withdrawal delirium on a psychiatric unit: Recommendations for management. Am J Drug Alcohol Abuse 2003; 29: 487–96.CrossRefPubMedGoogle Scholar
  35. 35.
    de Jong CAJ, Kamal R, Dijkstra BAG et al. Gamma-hydroxybutyrate detoxification by titration and tapering. Eur Addict Res 2012; 18: 40–5.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin 2017

Authors and Affiliations

  1. 1.Jüdisches Krankenhaus Berlin, Akademisches Lehrkrankenhaus der CharitéBerlinDeutschland

Personalised recommendations